United Kingdom (UK)
Recombinant monoclonal antibody to CD44. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma MF1-16-11.
UniProt Accession Number of Target Protein: P16070
Alternative Name(s) of Target: CDw44; Epican; Extracellular matrix receptor III; ECMR-III; GP90 lymphocyte homing/adhesion receptor; HUTCH-I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycoprotein 1; PGP-1
Immunogen: The original mouse antibody was raised by immunizing C57BL/6 mice with soluble CD44vRA. CD44vRA is a form of CD44, containing an extra alanine, derived from rheumatoid arthritis patients.
Specificity: This antibody is specific for CD44vRA, which is a CD44 derived from rheumatoid arthritis patients. CD44vRA contains an extra alanine. At higher concentration it will also bind to other isoforms of CD44. CD44 is cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.
Application Notes: The mouse version of this antibody was administred to arthritic mice to reduce joint inflammation. It also induced apoptosis above the spontaneous level in the spleen of the mice (Golan et al, 2007; pmid:17383158). To test the ability of this antibody to bind to CD44vRA, flow cytometry was preformed on Namalwa cells expressing different isoforms of CD44 (US2011207678). Flowcytometry was preformed with the mouse version of this antibody on synovial fluid cells and PBLs. The antibodies bound to the synovial fluid cells but not the PBLs from the same patient (Golan et al, 2007; pmid:17383158).
Antibody first published in:
Golan et al. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody J Autoimmun. Mar-May 2007;28(2-3):99-113. PMID:17383158
Note on publication:
Describes the generation of monoclonal antibodies (mAbs) that exclusively bind, at concentrations ranging from 2 to 100 microg/ml, to a modified CD44 variant (designated CD44vRA) expressed on synovial fluid cells from joints of rheumatoid arthritis (RA) patients.